Biomed Central Ltd

SHERPA: Unknown

People

  1. Schoenfeld
    Schoenfeld
  2. Budhu
    Budhu
  3. Khalil
    Khalil
  4. Dunn
    Dunn
  5. Voss
    Voss
  6. Rudin
    Rudin
  7. Carlo
    Carlo
  8. Kotecha
    Kotecha
  9. Mangarin
    Mangarin
  10. Panageas
    Panageas

Groups

  1. Hematology-Oncology Fellows (98)
  2. Department of Medicine (97)
  3. Solid Tumor Oncology Division (85)
  4. Weinberg Fellows (76)
  5. Hematologic Malignancies, Division of (49)
  6. GSK Faculty (43)
  7. Melanoma and Immunotherapeutics Service (30)
  8. Sloan Kettering Institute Postdocs (30)
  9. Graduate Medical Education (26)
  10. GME, Medicine (22)
Search Within
  1. "Hematology-Oncology Fellows"
Formats
  1. Journal Article (47)
  2. Meeting Abstract (42)
  3. Guidelines (4)
  4. Review (3)
  5. Editorial (1)
  6. Research Letter (1)
Groups
  1. Hematology-Oncology Fellows (98)
  2. Department of Medicine (97)
  3. Solid Tumor Oncology Division (85)
  4. Weinberg Fellows (76)
  5. Hematologic Malignancies, Division of (49)
  6. GSK Faculty (43)

More Groups

People
  1. Jedd Wolchok (21)
  2. Taha Merghoub (15)
  3. Adam Schoenfeld (11)
  4. Claire Friedman (10)
  5. Allison Betof Warner (9)
  6. Danny Khalil (9)

More People

Years
  1. 2025 (8)
  2. 2024 (6)
  3. 2023 (5)
  4. 2022 (22)
  5. 2021 (18)
  6. 2020 (21)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (75)
  2. Genome Medicine (5)
  3. Journal of Hematology & Oncology (5)
  4. Breast Cancer Research (3)
  5. BMC Cancer (2)
  6. Genome Biology (2)

More Publications

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)
    Journal Article

    McMillan, M. T.; Reyngold, M.; Crane, C. H.; O'Brien, D. A. R.; Williams, V. M.; Zinovoy, M.; Cuaron, J. J.; Gönen, M.; Kaiser, A.; Sopka, D. M.; more...
    BMC Cancer (2025)

    Fulltext@MSK | Save
  • Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL
    Journal Article

    Culbert, A. A.; Gava, F.; Valtis, Y. K.; Satta, T.; Vora, S.; Rocco, J. M.; Nussenblatt, V.; Silbert, S. K.; Shalabi, H.; Yates, B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Allele-specific HLA LOH in solid tumors: Distinct patterns by tumor type and potential prognostic relevance
    Journal Article

    Sewastianik, T.; Roy, C.; Gormally, M.; Montesion, M.; Halvey, P.; Jindal, A.; Lam, H.; Schoenfeld, A.; Klebanoff, C. A.; Opiteck, G. J.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
    Journal Article

    Nacev, B. A.; Bradic, M.; Woo, H. J.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Joint representation and visualization of derailed cell states with Decipher
    Journal Article

    Nazaret, A.; Fan, J. L.; Lavallée, V. P.; Burdziak, C.; Cornish, A. E.; Kiseliovas, V.; Bowman, R. L.; Masilionis, I.; Chun, J.; Eisman, S. E.; more...
    Genome Biology (2025)

    Fulltext@MSK | Save
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • The cold immunological landscape of ATM-deficient cancers
    Journal Article

    Sinha, S.; Ng, V.; Novaj, A.; Zhu, Y.; Yazaki, S.; Pei, X.; Derakhshan, F.; Pareja, F.; Setton, J.; Naulin, F.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
    Journal Article

    Middha, P.; Thummalapalli, R.; Quandt, Z.; Balaratnam, K.; Cardenas, E.; Falcon, C. J.; Princess Margaret Lung Group; Gubens, M. A.; Huntsman, S.; Khan, K.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
    Journal Article

    Kudelka, M. R.; Richards, A. L.; Friedlander, P.; Wolchok, J. D.; Moy, A. P.; Shoushtari, A. N.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
    Journal Article

    Naing, A.; Khalil, D.; Rosen, O.; Camidge, D. R.; Lillie, T.; Ji, R. R.; Stacey, A.; Thomas, M.; Rosen, L.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save